Generare builds a platform combining high-throughput cloning and sequencing to identify, express, and characterise novel small molecules from microbial genomes, generating structured data on their properties. The company is focused on expanding the accessible chemical space for drug discovery by creating a large-scale dataset of previously unexplored molecular diversity. Founded in 2023, Generare reports growing adoption of its platform among pharmaceutical and research organisations, with discovered molecules entering early-stage drug development. Its immediate plans include expanding its compound library, scaling its discovery capabilities, and hiring across a multidisciplinary team to meet demand. Financially, the company recently secured €20 million in a Series A to fund those growth initiatives.

Total raised

$29M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2026